• Теги
    • избранные теги
    • Компании44
      • Показать ещё
      Страны / Регионы9
      Разное10
      • Показать ещё
      Сферы4
      Издания2
      Люди3
      Международные организации3
15 сентября, 07:56

Monsanto в Европе и революция в России

Bayer наконец-то купил Monsanto! Казалось бы, в первую очередь это проблема для европейских фермеров. Чего волноваться нам? (14.09.2016)«Expert Online» Немецкий концерн Bayer объявил о заключении сделки с американским производителем генно-модифицированных семян и гербицидов Monsanto по цене $128 за акцию. Советы директоров обеих компаний единогласно одобрили слияние. ...Выручка объединенной структуры по итогам 2015 года могла бы достигнуть 23 млрд евро. После объединения компании будут совокупно контролировать около 30% мирового урожая. Акции Bayer на фоне информации о сделки прибыли 2,2%, Monsanto подорожали на 0,2%. (конец цитаты) Но с того дня, как 30% рынка сельхозпродукции окажутся под контролем двух фирм, в недалеком прошлом участвовавших в человеконенавистнических проектах: первая входила в концерн IG Farben (владел 42,5 % акций компании, которая производила Циклон Б), а вторая производила «Агента «оранж» для британской и американской армий, который распылялся с самолетов для уничтожения растительности на территории повстанцев. Неудивительно, что корпорации-носители такого прошлого теперь объединились в своей борьбе с населением планеты.

Выбор редакции
26 мая, 12:25

Под новым брендом: Химическое подразделение концерна Bayer обрело собственное имя

На мировом химическом рынке игрок под брендом Covestro появился совсем недавно - в сентябре 2015 года. Однако фирма эта отнюдь не новичок: до отделения от материнской компании Bayer Group производитель высокотехнологичных материалов на полимерной основе под названием Bayer MaterialScience был широко известен и имел представительства во многих странах мира, в том числе и в России. О том, как повлияло свободное плавание на деятельность компании, РГ рассказывают глава Covestro AG (Германия) Патрик Томас и генеральный директор ООО Ковестро в России и СНГ Музаффер Унвер. Подробнее читайте на нашем сайте www.oilru.com

25 мая, 00:11

Monsanto отказалась от предложения Bayer

Американская корпорация Monsanto отказалась от предложения по ее приобретению немецким химическим концерном Bayer за 62 миллиарда долларов. По словам главы Monsanto Хью Гранта, данное предложение существенно недооценивает компанию, а также не обеспечивает адекватного решения и страховки от потенциальных финансовых и регулятивных рисков, связанных с приобретением. Корпорация Monsanto, производящая гербициды и генномодифицированные семена сельскохозяйственных растений заявляет, что открыта для п… ЧИТАТЬ ДАЛЕЕ: http://ru.euronews.com/2016/05/24/monsanto-has-rejected-an-offer-from-bayer-agricultural-supplier euronews: самый популярный новостной канал в Европе. Подписывайтесь! http://www.youtube.com/subscription_center?add_user=euronewsru euronews доступен на 13 языках: https://www.youtube.com/user/euronewsnetwork/channels На русском: Сайт: http://ru.euronews.com Facebook: https://www.facebook.com/euronews Twitter: http://twitter.com/euronewsru Google+: https://plus.google.com/u/0/b/101036888397116664208/100240575545901894719/posts?pageId=101036888397116664208 VKontakte: http://vk.com/ru.euronews

19 марта 2015, 16:09

Who is winning the PR battle over neonicotinoids?

Bee campaigners scored a victory in the German courts, but chemical companies continue to fight the European Commission ban. Dominic Bates looks at who is winning the PR warWhen a judge ruled last week that an injunction be lifted on the German chapter of the Friends of the Earth (FoE) so it could criticise the “bee-friendly” claims of a chemical giant’s pesticides, campaigners hailed it as a victory for freedom of speech. “Bayer Group has been shown up as a corporate bully, trying to silence campaigners who are standing up for bees,” heralded a press release from the environmental group. But the case, which focused on two domestic plant sprays whose packaging claimed they were not harmful for bees, is just the latest battle in a public relations war over the environmental credentials of n eonicotinoids Related: Will the UK's pollinator strategy be enough to stop bee decline? Related: Do farmers really need bee-harming insecticides? Continue reading...

Выбор редакции
13 сентября 2013, 14:56

Bayer under investigation in China

German drugmaker probed over a ‘potential case of unfair competition’ as foreign pharmaceutical groups continue to come under scrutiny

01 августа 2013, 00:40

Bayer будет использовать СО2 как новое сырье в промышленности

На заводе в г. Дормаген (Германия) будут применять парниковые газы для производства высококачественных пластмасс. Это экологически и экономически более выгодный промышленный процесс, успешно проверенный на протяжении двух лет испытаний. Об этом «Хвиле» сообщила пресс-служба компании. Леверкузен (Германия), 31 июля 2013. После успешных испытаний, Bayer намерен внедрить использование углекислого газа, парникового газа, в качестве нового сырья для производства пластмасс. Компания приступила к разработке плана строительства нового промышленного объекта на своем заводе в Дормагене (Германия). Здесь CO2 будет применяться на этапе производства прекурсора для изготовления высококачественных пеноматериалов. Цель нового завода в Дормагене — изготовить достаточные объемы прекурсора для использования на производстве начиная с 2015 года. Применение углекислого газа принесет выгоду и пользу для окружающей среды. CO2 заменит некоторое ископаемое сырье, например исходные нефтепродуктов, для которых прежде не было альтернативы. В то же время Bayer ожидает, что новый процесс обеспечит экономические преимущества по сравнению с обычным способом производства. Вредные газы превращаются в прибыльное сырье «CO2 предстает в новом свете: продукты сжигания превращаются в полезное и выгодное сырье. Благодаря этому наша компания одной из первых в мире внедрила совершенно иной способ производства высококачественных пеноматериалов», — говорит Патрик Томас, генеральный директор Bayer MaterialScience. Углекислый газ получают от электростанции RWE Power, которая вместе с такими компаниями и учреждениями, как Bayer Technology Services, CAT Catalytic Center в Ахене и RWTH Аахенского университета, входит в число участников проекта. Производитель материалов сотрудничает с партнерами в промышленности и научных кругах, чтобы совершенствовать и развивать процесс, который интенсивно испытывался в течение последних двух лет. В рамках исследовательского проекта Dream Production, финансируемого государством, опытный завод из основного промышленного комплекса компании Bayer в Леверкузене производит небольшое количество полиолов — прекурсора, в котором CO2 химически связан. Вещество используется для производства пенополиуретана (поролона). Этот высококачественный материал применяется для изготовления множества предметов быта, среди которых мягкая мебель, комплектующие запчасти для автомобилей, холодильное оборудование, изоляционные материалы для зданий и проч. Внутренние тестирования новых пеноматериалов демонстрируют как минимум такое же высокое качество, что и обычные материалы, произведенные стандартным способом на основе нефтепродуктов. Матрасы произведенные при помощи CO2 «После успешного завершения испытаний мы перешли ко второй стадии — запуск в производство», — рассказывает Патрик Томас. Впервые новые эластичные пенополиуретаны на основе CO2 будут применяться для производства матрасов. Запланированный объем производственной площадки в Дормагене будет составлять порядка нескольких тысяч тонн. «Этого, конечно, недостаточно, чтобы удовлетворить рыночный спрос. Bayer зарегистрировал патент на данную технологию, но мы пока не решили, будет ли компания эксклюзивным производителем этого инновационного полиола. В будущем возможно и лицензирование», — добавляет Патрик Томас. О компании Bayer MaterialScience: Bayer MaterialScience — одна из крупнейших в мире компаний по производству полимеров. Продажи компании в 2012 году составили 11,5 млрд евро. Главные направления бизнес-деятельности — производство высокотехнологичных полимерных материалов, а также разработка инновационных решений для продуктов, используемых во многих сферах повседневной жизни. Основные сегменты — автомобилестроение, электротехника и электроника, строительство, спорт и досуг. К концу 2012 года компания Bayer MaterialScience насчитывала 30 производственных площадок и около 14 500 сотрудников во всем мире. Bayer MaterialScience входит в состав компании Bayer Group. Дополнительная информация: www.materialscience.bayer.com В Украине компания Bayer ведет бизнес с 1992 года. Команда из более чем 420 профессиональных сотрудников работает над тем, чтобы представить свои знания и инновации в области здравоохранения, сельского хозяйства и высокотехнологичных материалов. Дополнительная информация: www.bayer.ua

Выбор редакции
12 июля 2013, 20:43

Jacobs Receives Contract from Bayer - Analyst Blog

Jacobs receives a contract from Bayer CropScience Australia, the agricultural wing of the Bayer Group.

Выбор редакции
29 марта 2013, 21:56

What's Killing All The Bees?

Honeybee deaths are on the rise across the world, and researchers are working to find the cause. With as many as 40 or 50 percent of commercial U.S. bee hives lost to colony collapse disorder, according to the New York Times, scientists are eyeing a relatively new class of pesticides as a likely culprit. Neonicotinoids, which are chemically similar to nicotine, have already been shown to interfere with bees' capacity to learn scents, hampering their efforts to collect food. Colony collapse disorder -- which follows a "sudden loss of a colony’s worker bee population," according to the Environmental Protection Agency -- may be relatively new. It first surfaced around 2005, the New York Times explains, but has gotten dramatically worse in the past year. The European Commission has been pushing for a neonicotinoid pesticide ban in the EU, but chemical companies have been protesting. Syngenta and Bayer, two of the top producers of the pesticides, recently proposed a plan to expand bee habitats and increase monitoring in an attempt avoid restrictions on their products. In the U.S., a group of environmentalists and beekeepers recently filed suit against the EPA for approving the pesticides. Neonicotinoids, they wrote in the lawsuit, have been "repeatedly identified as highly toxic to honeybees, clear causes of major bee kills and significant contributors to the devastating ongoing mortality of bees known as colony collapse disorder,” reported Bloomberg. The U.S. Department of Agriculture is expected to issue its own assessment later in the spring, according to the New York Times. A recent study published by the American Bird Conservancy found that the pesticides may also negatively impact birds and water-borne insects. Mother Jones notes the report hasn't been peer-reviewed, but was authored by a retired senior research scientist formerly with Canada's environment ministry.

Выбор редакции
28 марта 2013, 20:45

Bee Pesticide Manufacturers Propose Plan To Aid Failing Colonies

By Emma Thomasson ZURICH, March 28 (Reuters) - Syngenta and Bayer , top producers of the pesticides blamed for a sharp fall in bee populations around the world, have proposed a plan to support bee health to try to forestall a European Union ban on the products. EU governments failed this month to agree a ban on three widely used pesticides linked to the decline of honeybees, but the European Commission is threatening to force one through unless member states agree a compromise. The Commission proposed a ban after the EU's food safety watchdog EFSA said neonicotinoids posed an acute risk to honeybee health, although it found no link between use of the pesticides and the phenomenon known as colony collapse disorder. "The Commission will wait to see the proposals from the companies, but as things stand, we believe the opinion from EFSA provides sufficient evidence to proceed with the proposed measures," said Commission health spokesman Frederic Vincent. Syngenta and Bayer, which say the impact of pesticides on bees is unproven and that a ban would deal a blow to the EU economy, proposed a plan to help end the stalemate that they hope will help bees and restore confidence in their products. Their plan includes the planting of more flowering margins around fields to provide bee habitats as well as monitoring to detect the neonicotinoid pesticides blamed for their decline and more research into the impact of parasites and viruses. "This comprehensive plan will bring valuable insights into the area of bee health, whereas a ban on neonicotinoids would simply close the door to understanding the problem," Syngenta Chief Operating Officer John Atkin said in a statement. Bees and other insects are crucial in pollinating most crops in Europe, but neonicotinoids are used on more than 8 million hectares to boost yields of rapeseed, wheat and other staples. Campaign group Avaaz, which has collected more than 2.5 million signatures on a petition for the EU to ban the products, was sceptical about the Syngenta and Bayer proposals. "Putting the pesticides industry in charge of protecting bees, is like putting a fox in charge of a henhouse," campaign director Alice Jay said in an emailed statement. "No one knows for certain what's killing our bees, but leading scientists have powerful evidence pointing to these pesticides," she said. "Protecting bees and our countryside must come before the profits of the pesticide industry." PARASITES OR PESTICIDES? The EU proposal would ban neonicotinoids on all crops except winter cereals and plants not attractive to bees, such as sugar beet. It would apply from July 1, 2013, ensuring this spring's maize sowing is unaffected, with a review after two years. While few deny that neonicotinoids can be harmful to bees, there are conflicting scientific opinions on the threat they pose under normal growing conditions. Some point to habitat decline and disease-carrying parasites such as the Varroa mite as the chief cause of bee deaths. "Even though all the evidence points to various parasites and diseases being the true cause of poor bee health, we are keen to do everything in our power to give consumers confidence in our products," said Ruediger Scheitza, head of strategy at Bayer CropScience. The Syngenta and Bayer plan would also include investment in new technologies to reduce dust emissions from the planting of seed treated with neonicotinoid products and more research into ways to fight bee parasites. A study funded by Syngenta and Bayer has showed a blanket ban on treating seeds with neonicotinoids would cut EU net wheat exports by 16 percent and lead to a 57 percent rise in maize imports, costing the EU economy 4.5 billion euros per year. Researchers have put the financial contribution of insect pollinators to the EU farming sector at 22 billion euros a year, and 153 billion euros globally. (Additional reporting by Charlie Dunmore in Brussels; Editing by Tom Pfeiffer and Mark Potter)

26 марта 2013, 15:32

Frontrunning: March 26

Berezovsky Died of Hanging Without Struggle, Police Say (BBG) BRICS Nations Plan New Bank to Bypass World Bank, IMF (BBG) China pledges more investments to Africa (FT) BOJ's Kuroda signals targeting longer-dated JGBs (Reuters) North Korea orders artillery to be combat ready, targeting U.S. bases (Reuters) Supreme Court to take up gay marriage for the first time (Reuters) U.S. Cracks Down on 'Forced' Insurance (WSJ) Japanese courts press Abe on electoral reform (FT) Vietnam accuses China of attack on fishermen in South China Sea (Reuters) Italy's High Court Overturns Knox Acquittal (WSJ) Facebook’s Zuckerberg Said to Explore Forming Political Group (BBG)   Overnight Media Digest WSJ * Dell Inc said it received two alternative acquisition proposals from Blackstone and activist investor Carl Icahn, following a $24.4 billion deal last month to be taken private by founder Michael Dell. * The BlackBerry Z10 phone from BlackBerry has received tepid marketing support from AT&T since its debut in stores on Friday, dealing the company an early setback in its drive to improve sales in the crucial U.S. market. * Boeing Co began the first in a series of 787 Dreamliner test flights on Monday, preparing for regulators to evaluate changes to its lithium-ion battery system and marking another step in the plane maker's effort to return the jet to commercial service. * Centrica Plc, one of the UK's main energy providers, has signed a deal to buy billions of cubic meters of liquefied natural gas from a U.S. plant, in the first deal clearly intended to bring gas from North America to the UK. * The U.S. Department of Transportation proposed a $1.7 million fine against Exxon Mobil Corp for failing to properly prepare for what the department says were known flooding risks to one of its pipelines that ruptured in 2011 and spilled 1,500 barrels of crude into Montana's Yellowstone River. * T-Mobile USA has become the first major wireless carrier in the United States to drop smartphone subsidies, moving away from a model that has helped companies like Apple Inc bank large profits at a steep cost to carriers' margins. * Oracle Corp on Monday said it agreed to acquire telecommunications software provider Tekelec, continuing a recent effort to profit from the explosion of smartphones and tablet computers burdening carriers' networks. * Beijing-based Li Ning Co Ltd said in a statement to the Hong Kong Stock Exchange that it plans to downsize after reporting a $318.8 million loss for 2012 and a 25 percent drop in revenue. * Online video site Hulu has had talks with several potential buyers including Guggenheim Partners, one of several options the company, owned by News Corp and Walt Disney Co, is considering as it tries to resolve uncertainty about its strategic direction. * A Kuwaiti sheik alleges that a senior executive at Switzerland's UBS AG offered $20 million to get the bank an advisory role on one of the biggest-ever acquisitions in the Middle East, but the bank later backed out of the deal, according to the sheik's testimony in a Dubai court case. * Canada's Bombardier Inc has condensed its production plans for a second, larger version of its CSeries jetliners to try to keep its tight schedule for the first deliveries of the new planes, according to people familiar with the matter. * Law firm Howrey LLP was in a "death spiral" for nearly two years, according to new lawsuits that claim the firm's partners didn't seem to know the depth of its financial problems.   FT Fund manager Schroders Plc is to pay 424 million pounds ($646 million) for smaller rival Cazenove Capital, as it moves to bulk up its private banking arm running money for wealthy clients. Michael Dell is willing to explore the possibility of working with Blackstone Group LP and Carl Icahn regarding alternative offers for Dell U.S. regulators approved Nasdaq OMX Group's $62 million compensation plan for firms that lost money in Facebook Inc's glitch-ridden market debut. Yahoo Inc has snapped up mobile news aggregator Summly, founded by 17-year-old Nick D'Aloisio two years ago from his home in London. Cynthia Carroll, the outgoing chief executive of Anglo American , warned mining industry shareholders to either get out of the sector or adjust their expectations. Dutch package delivery firm TNT Express said the sale process of its Chinese business is underway and that it is pursuing the sale of its Brazilian arm. Britain's Centrica Plc signed a long-term deal to import U.S. natural gas at a time when the domestic gas production continues to decline while U.S. output hits record highs.   NYT * Michael Dell considers Blackstone Group LP's preliminary proposal for Dell Inc to be potentially friendly to management and may reach out to talk later this week, a person briefed on the matter said on Monday. * Facebook Inc is no longer relying solely on what its users reveal. Instead, it is tapping outside data sources to learn even more about them, and to sell more finely targeted ads. * Concord Music Group, an independent music company with an artist roster that includes Paul McCartney, Paul Simon and Creedence Clearwater Revival, has been sold to Wood Creek Capital Management, a private equity firm that has been quietly building a collection of music assets. * Rengan Rajaratnam pleaded not guilty on Monday to insider trading charges while he worked for the now-defunct Galleon Group, coming nearly two years after the conviction of his older brother, the fallen hedge fund titan Raj Rajaratnam. * Shares in Bankia SA, the giant Spanish mortgage lender whose collapse last year led to a banking crisis in Spain, slumped on Monday in the first day of trading after regulators wiped out most of the stock's value. Regulators said on Friday that Bankia shares would be revalued at 1 cent each as the custodial managers who now oversee the bank try to create a clean slate. The new valuation was a condition of Bankia getting a capital injection of 10.7 billion euros ($13.9 billion) from European rescue funds. * A survey of 800 large and midsize employers including PepsiCo Inc and Wal-Mart Stores Inc found that employers are increasingly trying to lower healthcare costs by using incentives to persuade workers to make better lifestyle choices. * Puerto Rico has gone on a campaign to promote tax incentives that took effect last year, marketing its beautiful beaches, private schools and bargain costs in an effort to lure affluent American hedge fund managers and business executives to its shores. * Messages from the world's largest law firm, DLA Piper, disclosed in a dispute over fees, will likely add to a perception that law firms inflate bills by performing superfluous tasks and overstaffing assignment   Canada THE GLOBE AND MAIL * Companies hoping to snag a piece of the biggest roadwork contract in Quebec's history will first have to prove they're corruption-free, a major test for the province as it aims to fix its failing infrastructure while tackling graft in the construction industry. * Ontario premier Kathleen Wynne has stepped up her push for new taxes or tolls to pay for public transit expansion, warning that without such measures, badly needed infrastructure will never see the light of day. Reports in the business section: * Finance Minister Jim Flaherty says Canada is nearing an elusive free-trade agreement with South Korea, but some Canadian exporters warn they are years behind other countries that already have deals with the Asian manufacturing powerhouse. * Canada's New Democratic Party (NDP) is about to reintroduce legislation designed to ensure Canadian companies are not using conflict minerals in their supply chain - and that consumers can be certain their smartphones and other electronics are free of minerals fuelling violence in the Democratic Republic of the Congo. NATIONAL POST * Conservative MP Mark Warawa, who wants Canadian parliamentarians to condemn sex-selection abortions, is refusing to back down after his motion was deemed out of order last week by a House of Commons committee. Warawa is urging MPs to reverse that decision and allow a vote in the Commons on the issue. He will plead his case on Wednesday to the Commons' procedural affairs committee. FINANCIAL POST * The apparently lacklustre sales of BlackBerry's new flagship Z10 handset in the United States have caused some observers to wonder if the delayed launch in the smartphone maker's most important market have dealt a blow to its chance at a comeback.   China CHINA SECURITIES JOURNAL -- China Investment Corporation has signed a contract with Russian companies to work together in promoting infrastructure investment and development in far eastern Russia, according to an official announcement. -- Dongfeng Automobile Co Ltd reported a 95 percent fall in net profit to 21.7 million yuan and a 17 percent fall in revenue to 17.7 billion yuan in 2012, according to the company's annual report. -- Bright Dairy and Food Co. reported a 31 percent rise in 2012 net profit to 311 million yuan. The firm hopes to achieve 15.8 billion yuan in revenue this year. SHANGHAI SECURITIES NEWS -- China's inflation could fall to around 2 percent in March from a year earlier and the whole year number is likely to be around 2.6 percent, said Song Guoqing, member of the Central Bank Monetary Policy Committee, adding that gross domestic product (GDP) could grow 8.3 percent. -- China's Securities Regulatory Commission, Beijing branch said it will promote securities companies to list in the stock market. PEOPLE'S DAILY -- Chinese President Xi Jinping will be invited to the opening ceremony of the Boao Forum for Asia (BFA) Annual Conference 2013 and he will deliver a keynote speech. -- China should crack down on 'naked officials' -- officials who have most of their assets and close family abroad -- and seek to regulate and identify which cadres fall into this category.   Fly On The Wall 7:00 Market Snapshot ANALYST RESEARCH Upgrades BroadSoft (BSFT) upgraded to Market Perform from Underperform at Raymond JamesElectronic Arts (EA) upgraded to Overweight from Neutral at Piper JaffrayGreen Dot (GDOT) upgraded to Outperform from Market Perform at JMP SecuritiesLaSalle Hotel (LHO) upgraded to Outperform from Market Perform at BMO CapitalPeabody Energy (BTU) upgraded to Outperform from Market Perform at Raymond JamesRF Micro Devices (RFMD) upgraded to Outperform from Perform at Oppenheimer Downgrades Ashland (ASH) downgraded to Neutral from Buy at LongbowCabot Oil & Gas (COG) downgraded to Hold from Buy at StifelGordmans Stores (GMAN) downgraded to Hold from Buy at StifelGordmans Stores (GMAN) downgraded to Neutral from Overweight at Piper JaffrayKraton Performance (KRA) downgraded to Perform from Outperform at OppenheimerMagellan Health (MGLN) downgraded to Market Perform from Outperform at Raymond JamesMeadWestvaco (MWV) downgraded to Neutral from Buy at UBSSouthwestern Energy (SWN) downgraded to Hold from Buy at Stifel Initiations Brookfield Residential (BRP) initiated with a Buy at CitigroupFusion-io (FIO) initiated with a Perform at OppenheimerLuminex (LMNX) initiated with a Neutral at WedbushON Semiconductor (ONNN) initiated with a Buy at BofA/MerrillTRI Pointe Homes (TPH) initiated with an Outperform at FBR Capital HOT STOCKS Raytheon (RTN) said it will consolidate its businesses to streamline operations, and sees a workforce reduction of about 200 employees. The company also named Thomas Kennedy as COOMagellan Health Services (MGLN) said that Magellan Complete Care of Arizona, a joint venture owned 80% by Magellan and 20% by Vanguard/Phoenix Health Plan, was notified by the state of Arizona that it was not selected as the Regional Behavioral Health Authority in GSA6; Maricopa CountyOnyx Pharmaceuticals (ONXX) and Bayer (BAYRY) announced approval of Stivarga in Japan for the treatment of patients with metastatic colorectal cancerGreen Mountain (GMCR) appointed Michael Degnan Chief Legal Officer, General Counsel EARNINGS/GUIDANCE Companies that beat consensus earnings expectations last night and today include:Children's Place (PLCE), Gordmans Stores (GMAN) Companies that missed consensus earnings expectations include:Cascade Bancorp (CACB), U.S. Auto Parts (PRTS), Focus Media (FMCN) Companies that matched consensus earnings expectations include:AuRico Gold (AUQ), Sonic (SONC) NEWSPAPERS/WEBSITES The board of Hulu, which is owned by News Corp (NWSA) and Disney (DIS), has reached out to potential buyers to gauge interest in acquiring the company, according to Reuters. T-Mobile (DTEGY) has decided to drop smartphone subsidies, becoming the first major wireless carrier in the U.S. to do so, reports the Wall Street Journal. Several Supreme Court justices seemed skeptical about the practice of brand name pharmaceutical companies paying generic companies to keep their cheaper drugs off the market for a longer time, according to The New York Times. Zynga (ZNGA) CIO Debra Chrapaty is leaving the company to become CEO of Nirvanix, an enterprise cloud storage company, according to an AllThingsD report. SYNDICATE ARCA Biopharma (ABIO) files to sell $20M in common stock, warrantsArcos Dorados (ARCO) files to sell 2.3M shares of common stock for holdersCalumet Specialty Products (CLMT) files to sell 5.25M shares of common stockCoastal Contacts (COA) files to sell common stockRainmaker Systems (RMKR) files to sell $7.2M in common stockThe First Bancorp (FNLC) 662K share Spot Secondary priced at $16.25

Выбор редакции
24 марта 2013, 01:36

'Noid Rage & Angry Birds: EPA Sued over Declining Bees, Called on to Stop Bird Deaths

Heather CallaghanActivist Post As stated before in the news about the EU's heated debate over the use of neonicotinoids - a nicotine-like pesticide, the world's most widely used - there's hope for the bees because the issue is not going away. The buzz is growing in North America as well, but not from the bees who are disappearing due to Colony Collapse Disorder (CCD) - and neonicotinoids are just one smoking gun. A coalition of interest groups, activists and beekeepers took the issue into their own hands on Thursday to slash the use of bee-killing pesticides in an effort to protect them and the future of food. Pesticide Action Network (PAN), Center for Food Safety, Beyond Pesticides and four beekeepers are among the team who want bees safe from the chemicals that include clothianidin and thiamethoxam. Even if it takes suing the government. How are they able to bring a case against the Environment Protection Agency (EPA) for this problem?The claim is that the EPA is responsible for dropping the ball when they let the manufacturers Bayer Crop Science and Syngenta enter into conditional registration for their use and acted illegally to allow it. Those chemicals are no longer considered safe for pollinators - they are supposed to only kill pests. Paul Towers of PAN told TakePart: We are taking the EPA to court for its failure to protect bees from pesticides. Despite our best efforts to warn the agency about the problems posed by neonicotinoids, the EPA continued to ignore the clear warning signs of an ag system in trouble. google_ad_client = "pub-1897954795849722"; /* 468x60, created 6/30/10 */ google_ad_slot = "8230781418"; google_ad_width = 468; google_ad_height = 60; He blames pesticides for this year's California bee shortage and subsequent almond crop threat. He finds this to be reason alone to pay attention, but there are many more (below). He echoes the concerns in the EU - these aren't just periodic sprays that can be washed off (not that that would help) -- they're systemic chemicals applied on the seeds and throughout the plant's life. They are integrated into the plant and end up in the pollen and nectar. And, they end up in the corn that is used to make high fructose corn syrup - often fed to bees. This is what kills them - multiple studies have proven these very pesticides are involved in their decline. One even recreated CCD with extremely low amounts, and it only took weeks before the researchers saw the telltale signs: bees mysteriously gone except for a few dead ones nearby, and food stores with some young ones left in the hive. Towers says this class of pesticides remains in the soil and in the next planting.More from TakePart: This isn’t just a California problem. The finger pointing has been active across the country, including Ohio, where bees are needed to pollinate more than 70 crops, including apples, pumpkins and berries. Bee die offs there were rampant last spring. (Bayer, by the way, sponsored seminars for beekeepers in Ohio—a move that stung critics. Doh!) And the story is repeated from Illinois to the Carolinas. The Europeans are alarmed at bee population crashes as well, and tried to limit a trio of pesticides, but failed. What's worse, and something that is still under the radar - Silent Spring is back with a vengeance. The American Bird Conservancy (ABC) noticed bee, bird and aquatic death during independent review. They called on the EPA for a ban on Tuesday. Cynthia Palmer is their Pesticide Program Manager. She said: It is clear that these chemicals have the potential to affect entire food chains. The environmental persistence of the neonicotinoids, their propensity for runoff and for groundwater infiltration, and their cumulative and largely irreversible mode of action in invertebrates raise significant environmental concerns. She made a single corn kernel coated with the pesticide sound like a bird's version of cyanide pills - because that's all it takes to kill one. Even tiny wheat and canola grains can do that. And 1/10th of that amount during egg laying season can affect the entire reproductive cycle. They are asking people to be careful about birdseed too. For all those who say there's not enough evidence - definitely check out ABC's report indicating 200 studies pointing to neonicotinoids in animal death. Ignoring the threat makes the EPA sound complicit in mass ecological death. We're often told by companies like Monsanto that these pesticides or genetically modified plants are only designed to destroy the stomachs of insects - not comforting. When we consider that the treadmill of pesticide use is now killing birds from a single kernel, we have to wonder about the effects of chowing down hundreds of pounds of it each year in processed, boxed, fast foods and chemical produce. Also, neonicotinoids synergize with some fungicides heavily introduced in the mid-2000s when we saw a sharp bee drop-off. That makes fungicides more toxic to them and kills the immune response needed to withstand gut pathogens. This PAN writer explains the train wreck very well. For all the accolades Rachel Carson's Silent Spring received in the '60s, I think what she wanted was for it to affect change. The EPA, whom we pay to protect the environment, is not doing its job when they cater to big corporate interest despite the severe weakening of important ecological chain links. And most researchers agree that ecology is complicated; even just one aspect like bees and their hives. They don't like to point the finger at only one cause, but reflect that a variety of factors are at play. For instance, things that weaken the bees, leave them vulnerable to mites and disease, so it poses problems finding cause and effect. One has recently said that even with great change, it would be some years before we see the good 'ol days of thriving bees. google_ad_client = "ca-pub-1897954795849722"; /* 468x60, created 7/28/12 */ google_ad_slot = "9833874419"; google_ad_width = 468; google_ad_height = 60; Do you want a more direct way to help? It's not just a hobby - anyone can do it! Interestingly enough - especially if you live in the city. Check out this encouraging short vid about it by TakePart: Sources:http://www.takepart.com/article/2013/03/20/epa-sued-over-ongoing-bee-losses?cmpid=foodinc-fbhttp://www.abcbirds.org/newsandreports/releases/130319.htmlAmerican Bird Conservancy's Report:The Impact of the Nation’s Most Widely Used Insecticides on BirdsAlso see what's up in the EU:EU Bee-Killing Pesticide Ban Crumbles Under Corporate Interests Read other articles by Heather Callaghan var linkwithin_site_id = 557381; linkwithin_text='Related Articles:' Enter Your Email To Receive Our Daily Newsletter Close var fnames = new Array();var ftypes = new Array();fnames[0]='EMAIL';ftypes[0]='email';fnames[1]='FNAME';ftypes[1]='text';fnames[2]='LNAME';ftypes[2]='text';var err_style = ''; try{ err_style = mc_custom_error_style; } catch(e){ err_style = 'margin: 1em 0 0 0; padding: 1em 0.5em 0.5em 0.5em; background: FFEEEE none repeat scroll 0% 0%; font- weight: bold; float: left; z-index: 1; width: 80%; -moz-background-clip: -moz-initial; -moz-background-origin: -moz- initial; -moz-background-inline-policy: -moz-initial; color: FF0000;'; } var mce_jQuery = jQuery.noConflict(); mce_jQuery(document).ready( function($) { var options = { errorClass: 'mce_inline_error', errorElement: 'div', errorStyle: err_style, onkeyup: function(){}, onfocusout:function(){}, onblur:function(){} }; var mce_validator = mce_jQuery("#mc-embedded-subscribe-form").validate(options); options = { url: 'http://activistpost.us1.list-manage.com/subscribe/post-json? u=3ac8bebe085f73ea3503bbda3&id=b0c7fb76bd&c=?', type: 'GET', dataType: 'json', contentType: "application/json; charset=utf-8", beforeSubmit: function(){ mce_jQuery('#mce_tmp_error_msg').remove(); mce_jQuery('.datefield','#mc_embed_signup').each( function(){ var txt = 'filled'; var fields = new Array(); var i = 0; mce_jQuery(':text', this).each( function(){ fields[i] = this; i++; }); mce_jQuery(':hidden', this).each( function(){ if ( fields[0].value=='MM' && fields[1].value=='DD' && fields[2].value=='YYYY' ){ this.value = ''; } else if ( fields[0].value=='' && fields [1].value=='' && fields[2].value=='' ){ this.value = ''; } else { this.value = fields[0].value+'/'+fields[1].value+'/'+fields[2].value; } }); }); return mce_validator.form(); }, success: mce_success_cb }; mce_jQuery('#mc-embedded-subscribe-form').ajaxForm(options); }); function mce_success_cb(resp){ mce_jQuery('#mce-success-response').hide(); mce_jQuery('#mce-error-response').hide(); if (resp.result=="success"){ mce_jQuery('#mce-'+resp.result+'-response').show(); mce_jQuery('#mce-'+resp.result+'-response').html(resp.msg); mce_jQuery('#mc-embedded-subscribe-form').each(function(){ this.reset(); }); } else { var index = -1; var msg; try { var parts = resp.msg.split(' - ',2); if (parts[1]==undefined){ msg = resp.msg; } else { i = parseInt(parts[0]); if (i.toString() == parts[0]){ index = parts[0]; msg = parts[1]; } else { index = -1; msg = resp.msg; } } } catch(e){ index = -1; msg = resp.msg; } try{ if (index== -1){ mce_jQuery('#mce-'+resp.result+'-response').show(); mce_jQuery('#mce-'+resp.result+'-response').html(msg); } else { err_id = 'mce_tmp_error_msg'; html = ' '+msg+' '; var input_id = '#mc_embed_signup'; var f = mce_jQuery(input_id); if (ftypes[index]=='address'){ input_id = '#mce-'+fnames[index]+'-addr1'; f = mce_jQuery(input_id).parent().parent().get(0); } else if (ftypes[index]=='date'){ input_id = '#mce-'+fnames[index]+'-month'; f = mce_jQuery(input_id).parent().parent().get(0); } else { input_id = '#mce-'+fnames[index]; f = mce_jQuery().parent(input_id).get(0); } if (f){ mce_jQuery(f).append(html); mce_jQuery(input_id).focus(); } else { mce_jQuery('#mce-'+resp.result+'-response').show(); mce_jQuery('#mce-'+resp.result+'-response').html(msg); } } } catch(e){ mce_jQuery('#mce-'+resp.result+'-response').show(); mce_jQuery('#mce-'+resp.result+'-response').html(msg); } } } BE THE CHANGE! PLEASE SHARE THIS USING THE TOOLS BELOW

Выбор редакции
22 марта 2013, 17:38

US government sued over use of pesticides linked to bee harm

Beekeepers, conservation and food campaigners accuse Environmental Protection Agency of failing to protect the insectsThe US government is being sued by a coalition of beekeepers, conservation and food campaigners over pesticides linked to serious harm in bees.The lawsuit accuses the Environmental Protection Agency (EPA) of failing to protect the insects – which pollinate three-quarters of all food crops – from nerve agents that it says should be suspended from use. Neonicotinoids, the world's most widely used insecticides, are also facing the prospect of suspension in the European Union, after the health commissioner pledged to press on with the proposed ban despite opposition from the UK and Germany."We have demonstrated time and time again over the last several years that the EPA needs to protect bees," said Peter Jenkins, an attorney at the Centre for Food Safety who is representing the coalition. "The agency has refused, so we've been compelled to sue.""America's beekeepers cannot survive for long with the toxic environment EPA has supported," said Steve Ellis, a Minnesota and California beekeeper and one of the plaintiffs who filed the suit at the federal district court. "Bee-toxic pesticides in dozens of widely used products, on top of many other stresses our industry faces, are killing our bees."The EPA declined to comment on the lawsuit, but said in a statement: "We are working aggressively to protect bees and other pollinators from pesticide risks through regulatory, voluntary and research programmes. Specifically, the EPA is accelerating the schedule for registration review of the neonicotinoid pesticides because of uncertainties about them and their potential effects on bees." However, even the accelerated review will not be completed before 2018.The pesticides named in the lawsuits are clothianidin, manufactured by Bayer, and thiamethoxam, made by Syngenta. Neither company chose to comment on the lawsuit, but industry group Crop Life America (CLA) is representing some of the companies."The CLA fully supports and trusts the rigour of EPA's review process for crop protection products, including neonicotinoids," said Ray McAllister, senior director of regulatory affairs at CLA. "This class of product represents an important component of modern agriculture that helps farmers protect their crops. Neonicotinoids are thoroughly tested and monitored for potential risks to the environment and various beneficial species, including honeybees."A series of high-profile scientific studies in the last year have increasingly linked neonicotinoids to harmful effects in bees, including huge losses in the number of queens produced, and big increases in "disappeared" bees that fail to return from foraging trips. Disease and habitat loss are also thought to be factors in the recent declines in populations of bees and other pollinators.A proposal to suspend the use of three neonicotinoids across the EU ended in a hung vote on 15 March. But Tonio Borg, the European commissioner for health and consumer policy, said this week he would take the proposal to appeal. If member states maintained their positions, the insecticides would be suspended. "The health of our bees is of paramount importance," said Borg. "We have a duty to take proportionate yet decisive action to protect them wherever appropriate."The lawsuit against the EPA argues that, via "conditional registrations", the regulator rushed the neonicotinoids into the market without sufficient examination and since that time has failed to take account of new information. "Pesticide manufacturers use conditional registrations to rush bee-toxic products to market, with little public oversight," said Paul Towers, at Pesticide Action Network, part of the coalition.The action by the coalition, which also includes the Sierra Club and the Centre for Environmental Health, follows an emergency petition in March 2012 which demanded the EPA suspend the use of clothianidin but was not acted upon. Also issued this week was a report from the American Bird Conservancy, which said the "EPA risk assessments have greatly underestimated [the risk to birds], using scientifically unsound, outdated methodology."BeesWildlifeInsectsPesticidesFarmingUS Environmental Protection Agency (EPA)United StatesDamian Carringtonguardian.co.uk © 2013 Guardian News and Media Limited or its affiliated companies. All rights reserved. | Use of this content is subject to our Terms & Conditions | More Feeds

17 марта 2013, 19:27

EU Bee-Killing Pesticide Ban Crumbles Under Corporate Interests

Heather CallaghanActivist Post It was January of this year that the European Food Safety Authority turned heads with their confirmation that neonicotinoids - insecticides derived from chemicals related to nicotine - are a smoking gun in the massive bee die off - also known as Colony Collapse Disorder (CCD). Multiple around-the-world studies and documentaries have implicated these pesticides in massive bee death since 2006, causing a great debate in the EU. Activists, environmentalists, scientists and even politicians were shocked and dismayed that the two-year ban suggested by the European Commission didn't pass on Friday. Major countries like UK and Germany failed to back the ban in the vote, arousing suspicions that they catered to industry interests - manufactures Bayer and Syngenta, and Big Ag groups in denial.Hungary and Romania led the opposed votes. Outspoken activist group Avaaz (dot org) finds the UK public wants this ban. A poll on Wednesday showed three-quarters of the UK supporting the ban and Avaaz amassed 2.5 million signatures across Europe. Iain Keith of Avaaz said: Britain and Germany have caved in to the industry lobby and refused to ban bee-killing pesticides. Today's vote flies in the face of science and public opinion and maintains the disastrous chemical armageddon on bees, which are critical for the future of our food. google_ad_client = "pub-1897954795849722"; /* 468x60, created 6/30/10 */ google_ad_slot = "8230781418"; google_ad_width = 468; google_ad_height = 60; Chemical companies Bayer and Syngenta lead the billion dollar neonicotinoids market. They were relieved and happy about the fall through. John Atkin, Syngenta's chief operating officer said: We are pleased member states did not support the EC's shamefully political proposal. Restricting the use of this vital crop protection technology will do nothing to help improve bee health. A spokeswoman for the Department for Environment, Food and Rural Affairs felt there should be more scientific evidence before such a big move that might rock the ag industry. However, since bees pollinate and help create one-third of the produce in the West, three-quarters globally, years of mass die off would seem to be the biggest priority for agriculture to continue. The US and UK have experienced a 50% bee drop-off in the last 25 years. And there is lots of alarming scientific evidence. This mindset is upsetting to people like Prof. Dave Goulson,  leader of one of the major studies pointing to neonicotinoids for bee die-off. Scientists scramble to provide proof with 6-month or longer studies, but as he says, "this class of pesticides were not adequately evaluated in the first place. Yet politicians choose to ignore all of this." He believes it is mainly the manufacturers refusing to acknowledge the critical harm. A major Harvard School of Public Health study presented convincing evidence last year that an extremely low amount of neonicotinoids (imidacloprid is the world's most used) caused CCD. They even recreated CCD with the signature keynotes: bees have disappeared except for a few dead ones nearby and food stores are still in hive with some young ones and pollen. The two culprits: exposure to neonicotinoids through pollen and nectar and through high fructose corn syrup which is often fed to bees by bee keepers (neonicotinoids are systemically used on corn).They didn't die off at first, but did with periodic low amounts of exposure at 23 weeks. The study leaders estimated that continuing massive die-off could result in a loss of billions of dollars to the ag industry. Bottom line: these pesticides simply don't do what's intended if they kill the co-creators of the world's food supply (the ones who are not the pests!)Groups like Avaaz argue that short-term farming setbacks now to stop using neonicotinoids far outweigh a future mass farming loss if the bee population continues to rapidly decline. It's not just about the bees themselves, a major concern, but the very future of food. While this ban would have applied to all 27 member states, some of the countries like France, Germany, Italy and Slovenia have voted for their own suspensions in the past. There was no majority for or against the ban in the final tally. Even though the ban fell through, an appeals committee still has the power to enforce it. If the appeals vote ends up "hung" again, the commission can make its own decision (unfortunately this is how genetically modified crops were approved in the EU). Or the EC could simply revise the proposal and come back. A UK environment secretary was frustrated that the EC was rushing this decision instead of waiting for pending field trial results for another study. The study's control fields were actually compromised by drifting pesticides! Or at least the neonicotinoids were found in the control pollen and nectar somehow. Furthermore, pesticide regulation is shoddy. And the focus of any investigation is on pesticide sprays and minimal species of bees. Neonicotinoids are systemic chemicals used even on the seeds and are found in the pollen and nectar. The focus leaves out other important species for pollination like other bees, different types of flies and butterflies. But Belgian Green party EU parliament member Bart Staes said: The inconclusive outcome keeps hopes alive that the proposed neonicotinoids suspensions can be implemented soon. We call on all reluctant EU governments not to heed the misleading lobbying from the insecticide industry. And with growing public awareness, outlook is hopeful. Continuing bee deaths means the issue is not going away.Read more about Prof. Goulsen's 2012 study and why he's angry at Bayer:http://www.guardian.co.uk/environment/2012/mar/29/crop-pesticides-honeybee-declineFurther reading:Nature Studies by Michael McCarthy: Have we learned nothing since 'Silent Spring'?Article Source:http://www.guardian.co.uk/environment/2013/mar/15/bee-harming-pesticides-escape-european-banImage: Modified by author, original: http://cascadiansourcecenter.com/photo/gas-mask-on-beeRead other articles by Heather Callaghan var linkwithin_site_id = 557381; linkwithin_text='Related Articles:' Enter Your Email To Receive Our Daily Newsletter Close var fnames = new Array();var ftypes = new Array();fnames[0]='EMAIL';ftypes[0]='email';fnames[1]='FNAME';ftypes[1]='text';fnames[2]='LNAME';ftypes[2]='text';var err_style = ''; try{ err_style = mc_custom_error_style; } catch(e){ err_style = 'margin: 1em 0 0 0; padding: 1em 0.5em 0.5em 0.5em; background: FFEEEE none repeat scroll 0% 0%; font- weight: bold; float: left; z-index: 1; width: 80%; -moz-background-clip: -moz-initial; -moz-background-origin: -moz- initial; -moz-background-inline-policy: -moz-initial; color: FF0000;'; } var mce_jQuery = jQuery.noConflict(); mce_jQuery(document).ready( function($) { var options = { errorClass: 'mce_inline_error', errorElement: 'div', errorStyle: err_style, onkeyup: function(){}, onfocusout:function(){}, onblur:function(){} }; var mce_validator = mce_jQuery("#mc-embedded-subscribe-form").validate(options); options = { url: 'http://activistpost.us1.list-manage.com/subscribe/post-json? u=3ac8bebe085f73ea3503bbda3&id=b0c7fb76bd&c=?', type: 'GET', dataType: 'json', contentType: "application/json; charset=utf-8", beforeSubmit: function(){ mce_jQuery('#mce_tmp_error_msg').remove(); mce_jQuery('.datefield','#mc_embed_signup').each( function(){ var txt = 'filled'; var fields = new Array(); var i = 0; mce_jQuery(':text', this).each( function(){ fields[i] = this; i++; }); mce_jQuery(':hidden', this).each( function(){ if ( fields[0].value=='MM' && fields[1].value=='DD' && fields[2].value=='YYYY' ){ this.value = ''; } else if ( fields[0].value=='' && fields [1].value=='' && fields[2].value=='' ){ this.value = ''; } else { this.value = fields[0].value+'/'+fields[1].value+'/'+fields[2].value; } }); }); return mce_validator.form(); }, success: mce_success_cb }; mce_jQuery('#mc-embedded-subscribe-form').ajaxForm(options); }); function mce_success_cb(resp){ mce_jQuery('#mce-success-response').hide(); mce_jQuery('#mce-error-response').hide(); if (resp.result=="success"){ mce_jQuery('#mce-'+resp.result+'-response').show(); mce_jQuery('#mce-'+resp.result+'-response').html(resp.msg); mce_jQuery('#mc-embedded-subscribe-form').each(function(){ this.reset(); }); } else { var index = -1; var msg; try { var parts = resp.msg.split(' - ',2); if (parts[1]==undefined){ msg = resp.msg; } else { i = parseInt(parts[0]); if (i.toString() == parts[0]){ index = parts[0]; msg = parts[1]; } else { index = -1; msg = resp.msg; } } } catch(e){ index = -1; msg = resp.msg; } try{ if (index== -1){ mce_jQuery('#mce-'+resp.result+'-response').show(); mce_jQuery('#mce-'+resp.result+'-response').html(msg); } else { err_id = 'mce_tmp_error_msg'; html = ' '+msg+' '; var input_id = '#mc_embed_signup'; var f = mce_jQuery(input_id); if (ftypes[index]=='address'){ input_id = '#mce-'+fnames[index]+'-addr1'; f = mce_jQuery(input_id).parent().parent().get(0); } else if (ftypes[index]=='date'){ input_id = '#mce-'+fnames[index]+'-month'; f = mce_jQuery(input_id).parent().parent().get(0); } else { input_id = '#mce-'+fnames[index]; f = mce_jQuery().parent(input_id).get(0); } if (f){ mce_jQuery(f).append(html); mce_jQuery(input_id).focus(); } else { mce_jQuery('#mce-'+resp.result+'-response').show(); mce_jQuery('#mce-'+resp.result+'-response').html(msg); } } } catch(e){ mce_jQuery('#mce-'+resp.result+'-response').show(); mce_jQuery('#mce-'+resp.result+'-response').html(msg); } } } BE THE CHANGE! PLEASE SHARE THIS USING THE TOOLS BELOW

15 марта 2013, 16:37

Bee-harming pesticides escape proposed European ban

Commission proposal to suspend use of neonicotinoids fails to gain majority, but could still be enforced by appeals committeeA European attempt to ban the world's most widely used insecticides that have been linked to serious harm in bees has failed.The European commission proposed a two-year suspension of neonicotinoids after the European Food Safety Authority (EFSA) deemed their use an unacceptable risk, but major nations including UK and Germany failed to back the plan in a vote on Friday.The result leaves environmental campaigners, scientists and some politicians bitterly disappointed."Britain and Germany have caved in to the industry lobby and refused to ban bee-killing pesticides," said Iain Keith, at campaign group Avaaz. "Today's vote flies in the face of science and public opinion and maintains the disastrous chemical armageddon on bees, which are critical for the future of our food."The chemical companies that dominate the billion-dollar neonicotinoid market, Bayer and Syngenta, were relieved. Syngenta chief operating officer, John Atkin, said: "We are pleased member states did not support the EC's shamefully political proposal. Restricting the use of this vital crop protection technology will do nothing to help improve bee health."A Bayer spokesman, describing the company as a "responsible corporate citizen" said: "The EC has relied too heavily on the precautionary principle, without taking the principle of proportionality into account."A spokeswoman for the Department for Environment, Food and Rural Affairs defended the UK's abstention: "Bee health is extremely important but decisions must be based on sound scientific evidence and rushing this through could have serious unintended consequences both for bees and for food production. We are not opposing the EU's proposals. But as we do not have the evidence yet it is impossible for us to vote either way."But Prof Dave Goulson, at the University of Stirling and who led one of the key studies showing that neonicotinoids harm bumblebees, told the Guardian: "The independent experts at EFSA spent six months studying all the evidence before concluding there was an unacceptable risk to bees. EFSA and almost everybody else – apart from the manufacturers – agree this class of pesticides were not adequately evaluated in the first place. Yet politicians choose to ignore all of this."About three-quarters of global food crops rely on bees and other insects to fertilise their flowers, so the decline of honeybee colonies due to disease, habitat loss and pesticide harm has prompted serious concern.Conservationists argue that the harm resulting from the loss of bees and the vital pollination service they provide outweighs any farming losses. Almost three-quarters of the UK public backed the proposed ban, according to a poll released on Wednesday, and Avaaz had amassed 2.5m signatures across Europe in support.The EC proposal was to ban the use of three neonicotinoids from use on corn, oil seed rape, apples, carrots, strawberries and many other flowering crops across the continent for two years, after which the situation would be reviewed.Suspensions have previously been put in place in France, Germany, Italy and Slovenia, but the EC proposal would have applied across all 27 member states. Many major agricultural nations, including France, Italy, Spain, the Netherlands and Poland, voted for the ban, while the UK and Germany abstained, with Hungary and Romania leading those opposed.However, the ban could still be enforced within months if the EC takes the decision to an appeals committee. Friday's vote, by member states' experts on the standing committee on the food chain and animal health, saw 13 nations in favour of the ban, five abstaining and nine opposing, meaning there was no majority for or against.The same "hung" vote at the appeals committee would mean the EC could enforce the ban. "When member states do not want to take a decision, then the commission does it, as it has in approving genetically modified crops," a source told the Guardian.EC officials said: "The commission takes note of the member states' response to its proposal but remains committed to ambitious and proportionate legislative measures." It said it would decide whether to go to appeal, or revise the proposal, in the next week.Bart Staes, a Green party MEP in Belgium said: "The inconclusive outcome keeps hopes alive that the proposed neonicotinoid suspensions can be implemented soon. We call on all reluctant EU governments not to heed the misleading lobbying from the insecticide industry."A series of high-profile scientific studies in the last year has increasingly linked neonicotinoids to harmful effects in bees, including huge losses in the number of queens produced, and big increases in "disappeared" bees – those that fail to return from foraging trips.The UK's environment secretary, Owen Paterson, faced criticism from one of his Conservative predecessors. Lord Deben, who as John Gummer was environment secretary, said: "If ever there were an issue where the precautionary principle ought to guide our actions, it is in the use of neonicotinoids. Bees are too important to our crops to continue to take this risk."Paterson said in February: "I have asked the EC to wait for the results of our field trials, rather than rushing to a decision." However, the results were not available at Friday's meeting because the field trials have been seriously compromised by contamination from neonicotinoids. Prof Ian Boyd, Defra's chief scientist, said: "At the control site, there were residues of neonicotinoids in pollen and nectar."Evidence submitted to an ongoing parliamentary inquiry in the UK cites a long list of failings in the existing regulation of neonicotinoids. Currently, only the effects on honeybees are considered, despite 90% of pollination being performed by different species, such as solitary or bumblebees, hoverflies, butterflies, moths and others. Another failing is that the regime was set up for pesticide sprays, not systemic chemicals like neonicotinoids that are used to treat seeds and then spread through the growing plant.Even the National Farmers Union, which argues that there is no need for change, admitted: "It is very well-known that the current pesticide risk assessment systems for bees were not developed to assess systemic pesticides." On Friday, the NFU's Chris Hartfield said: "We maintain that the proposed ban is not a proportionate response to the evidence we have available."BeesPesticidesInsectsFarmingWildlifeEuropean commissionEuropean UnionEuropeFoodDamian Carringtonguardian.co.uk © 2013 Guardian News and Media Limited or its affiliated companies. All rights reserved. | Use of this content is subject to our Terms & Conditions | More Feeds

31 января 2013, 20:32

EU proposes to ban insecticides linked to bee decline

Three neonicotinoids, the world's most widely used insecticides would be forbidden across the continent for two yearsInsecticides linked to serious harm in bees could be banned from use on flowering crops in Europe as early as July, under proposals set out by the European commission on Thursday, branded "hugely significant" by environmentalists. The move marks remarkably rapid action after evidence has mounted in recent months that the pesticides are contributing to the decline in insects that pollinate a third of all food.Three neonicotinoids, the world's most widely used insecticides, which earn billions of pounds a year for their manufacturers, would be forbidden from use on corn, oil seed rape, sunflowers and other crops across the continent for two years.It was time for "swift and decisive action", said Tonio Borg, commissioner for health and consumer policy, who added that the proposals were "ambitious but proportionate".The proposals will enter EU law on 25 February if a majority of Europe's member states vote in favour. France and the Netherlands are supportive but the UK and Germany are reported to be reluctant."It's important that we take action based upon scientific evidence rather than making knee-jerk decisions that could have significant knock-on impacts," said the environment secretary, Owen Paterson. "That's why we are carrying out our own detailed field research to ensure we can make a decision about neonicotinoids based on the most up-to-date and complete evidence available."Luis Morago, at campaign group Avaaz which took an anti-neonicotinoid petition of 2.2m signatures to Brussels, said: "This is the first time that the EU has recognised that the demise of bees has a perpetrator: pesticides. The suspension could mark a tipping point in the battle to stop the chemical armageddon for bees, but it does not go far enough. Over 2.2 million people want the European commission to face-down spurious German and British opposition and push for comprehensive ban of neonicotinoid pesticides."Keith Taylor, Green party MEP for South East England MEP, said: "For too long the threat to bees from neonicotinoids has been dismissed, minimised or ignored. It is, therefore, good to see the European commission finally waking up. Bees have enormous economic value as pollinators and are vital to farmers. Let us hope that we're not too late in halting the dramatic decline in their population."Scientific evidence has mounted rapidly since March 2012, when two high-profile studies found that bees consuming neonicotinoids suffered an 85% loss in the number of queens their nests produced and showed a doubling in "disappeared" bees who got lost while foraging. Neonicotinoids have been fiercely defended by their manufacturers, who claim there is no proof of harm in field conditions and by farming lobbies who say crop yields could fall without pesticide protection. Some neonicotinoid uses have been banned in the past in France, Italy, Slovenia and Germany, but no action has yet been taken in the UK. A parliamentary committee is currently investigating the impact of neonicotinoids on all pollinators and found evidence raising "serious questions about the integrity, transparency and effectiveness of EU pesticides regulation".On 16 January, the European Food Safety Authority, official advisers to the EC, labelled the three neonicotinoids an unacceptable danger to bees feeding on flowering crops and this prompted the proposal produced on Thursday. If approved by experts from member states on 25 February, it would suspend the use imidacloprid and clothianidin, made by Bayer, and thiamethoxam, made by Syngenta, on crops that attract bees. Winter cereals would be excluded, because bees are not active at that time, and the suspension would be reviewed after two years. The European commission is also considering banning gardeners from using these neonicotinoids, although B&Q, Homebase and Wickes have already withdrawn such products from their garden centres in the UK."This hugely significant proposal promises a first, important step on the road to turning around the decline on our bees," said Friends of the Earth's head of campaigns Andrew Pendleton. "The UK government must throw its weight behind it. The evidence linking neonicotinoid chemicals to declining bee populations is growing. It is time to put farmers and nature before pesticide company profits. Ministers must act quickly to support safe and effective alternatives to chemical insecticides."BeesWildlifeInsectsConservationPesticidesFarmingFoodDamian Carringtonguardian.co.uk © 2013 Guardian News and Media Limited or its affiliated companies. All rights reserved. | Use of this content is subject to our Terms & Conditions | More Feeds

11 января 2013, 21:00

Margaret Anderson: Top 10 Medical Research Trends to Watch in 2013

1. Federal funding: Fasten your seatbelts, it's going to be a bumpy ride. Congress has pushed the date of the "sequester" off another two months, delaying the prospect of automatic 8.2 percent cuts in the budgets of NIH, FDA, and other federal science programs. But a sequester (or other cuts) could still happen. Consider that current funding for these programs expires in March, the FY14 budgets are still being drafted, and there will likely be a fight over the debt ceiling. Advocates need to keep making noise to make a compelling case for the critical importance of medical research. The health of our citizens and the economic and fiscal health of the nation are at stake. Resources are available on our Sequestration Station website; also check out our Time Equals Lives social media campaign, where you can contribute your story to show our leaders why medical research matters, because we will all be patients eventually. 2. FDA: Recalibrating the benefit-risk equation. Patient groups have been saying for years that people living with a disease are often willing to accept more risk than the FDA is generally willing to tolerate in a new product. Well, now the agency can do something about it. In 2012, the latest reauthorization of PDUFA created a new "Patient-Focused Drug Development" initiative at the FDA, which allows the FDA to formally consult with patients -- initially in 20 disease areas -- about what their priorities are and what tradeoffs they are willing to accept. It may not sound revolutionary, but it could represent the beginning of a paradigm shift in the regulatory process if they get the process right, and if we don't get bogged down in fighting over what the 20 disease areas are. This will be an important initiative to track and be active in this year, and an important area for the FDA to focus on across its enters. By the way, we heard at Partnering for Cures that nobody thanks the FDA -- so here we go! Way to go, FDA, on a second year in a row of 30-plus new drug approvals. If they do it again in 2013, is it a trend? Saying thank you to FDA's Janet Woodcock 3. Financial innovation: Attack of the megafund. In October 2012, MIT finance professor Andrew Lo and colleagues proposed creation of a $30 billion "megafund" to bridge the translational research-finance gap by using financial engineering to securitize a highly diversified portfolio of therapies in development, an idea FasterCures got a preview of at its Financial Innovations Lab in July 2011. The model securitizes a portfolio of research assets as collateral to raise funds in the capital markets using a mix of debt and equity that appeal to a variety of investors' risk-reward ratios. Is this the kind of large-scale solution required for the big problem of financing risky research, particularly at the early stages? Lo plans a conference in 2013 to further develop the idea. Stay tuned for more work in this area by FasterCures and the Milken Institute in 2013, because this is one of the issues we are hearing the most consternation about. 4. Reimbursement: Can value drive innovation? Concerns in the pharma industry about the impact of reimbursement on their upstream R&D strategies are escalating, as efforts to rein in health-care costs are gaining steam. But do medical progress and the quality of care have to be sacrificed on the altar of cost-cutting? We heard some interesting discussion in 2012 from former pharma exec Frank Douglas and his new Austen BioInnovation Institute in Akron about the concept of "value-driven engineering" in medical devices, based on the principles of clinical utility, reduced complexity, and cost savings and efficiency. Douglas believes this framework can be applied to drug development as well. Can we shorten the time from molecule to hu(man) to ultimately drive down costs for payers? Will a focus on value be an innovation killer, as some fear, or can it be a disruptive driver for companies to tackle risky areas of high unmet need and first-in-class therapies? What is the methodology for deciding value? Where do patients fit into the equation? We look forward to more broad-based discussions of -- and hopefully more answers to -- these critical issues in 2013, as reimbursement could be our next cliff, if we survive the fiscal one. 5. Venture philanthropy: Playing in the major leagues. FasterCures has been tracking and supporting the rise of venture philanthropy in medical research for almost a decade, and these strategic, patient-driven research funders have hit the big leagues and gotten the attention of the large pharma companies. Small companies have found them valuable sources of seed capital and other non-financial assets for some time, but large pharma has been slower to understand what they bring to the table. 2012 saw the Cystic Fibrosis Foundation (fresh off a big success investing in Vertex's newly-approved drug Kalydeco) invest $58 million in Pfizer's research into therapies targeting the most common CF subtype (yes, you read that right -- the foundation is funding Pfizer), and Sanofi awarded $300,000 to a team of patient groups to create a cross-disease registry to accelerate translational research. Companies like Merck Serono and Celgene are working with nonprofits like the National MS Society and the Leukemia and Lymphoma Society as "talent scouts" of sorts to identify promising early-stage research. As foundation head Bonnie Addario advised a company CEO at Partnering for Cures in November, "Put us on your boards -- we put you on ours!" We call that speaking truth to power. 6. Academic research: Let's see you do that again.   Industry and investors are becoming increasingly frustrated with the lack of reproducibility of positive results from academic science published in peer-reviewed journals. In 2012, Amgen could not reproduce the results of 47 out of 53 so-called "landmark" oncology studies, and in 2011 Bayer discontinued 65 percent of its target validation projects when its results did not match published experiments. Some patient groups, like the ALS Therapy Development Institute and the Chordoma Foundation, have made replication of published results and validation of research products a core piece of their missions. Some investors are funding their own "killer experiments" before making investment decisions, and efforts like Science Exchange's Reproducibility Initiative are cropping up to find ways to systematically address the disincentives for academic researchers to validate their findings. Expect this debate to get louder in 2013 -- and hopefully coalesce around some productive solutions. 7. Data standards: Coming soon to a therapeutic area near you.  We hear over and over again that medical research desperately needs standards for collecting and analyzing data, but it's always seemed like a bite too big to chew. But the Critical Path Institute and CDISC are stepping up to the plate with CFAST, the Coalition for the Advancement of Standards and Therapies, in partnership with the FDA and the new industry consortium TransCelerate. We first heard about it at Partnering for Cures 2011, and it formally launched in October 2012, but it already has standards in seven therapeutic areas (out of 55 targeted) in various states of development. Watch for accelerated progress in 2013. 8. The other translation gap: Turning outputs into outcomes. FasterCures has spent a lot of time focusing on the "first translation gap," between basic scientific discoveries and research in humans subjects; somewhat outside our scope has been "T2," the gap between approval of a treatment and its adoption into widespread use to improve patient outcomes, which can take as long as the R&D process. Many others have analyzed this problem, but the ImproveCareNow network has gone from analysis to action, creating a rapid learning system that is speeding the adoption of evidence-based care practices for kids with Crohn's disease and ulcerative colitis at almost 50 care centers across the country and improving their health dramatically. The Kauffman Foundation is working to scale and replicate their success through its Health Network Trust initiative. We hope 2013 will see this model launched in other disease areas. 9. Collaboration: Writing the playbook. There now seems to be broad acceptance of the idea that collaboration among R&D stakeholders (government, academia, industry, nonprofits) is required if we are going to make progress in an increasingly complex scientific and business environment. There are many experiments in collaboration going on, and many successful outcomes that can be highlighted. It is time for more systematic analysis of what's working and what's not. While these efforts vary widely depending on the goals and the collaborators, can we draw some common lessons about, for example, what are fertile areas for collaboration, what one should look for in partners, what are the pitfalls to avoid? After all, as Luke Timmerman of Xconomy wrote recently, what we're after isn't collaboration for its own sake, it's a "creative rethinking of the biomedical R&D continuum," and "while those [collaborative] efforts are encouraging, this really should be a national conversation that involves a whole lot more players." Will 2013 be the year we start trying to know what we know, and perhaps even start redrawing that linear R&D pipeline we all know so well? 10. Innovation: Who's outside the box (you tell us). While there's no shortage of brilliant scientists and discoveries in medical research, it can be notoriously hard to move them forward in the expensive environments of academia and industry, where risk is not necessarily rewarded. We are seeing more efforts to try to bust out of this box in ways that are more common in other fields. Philanthropist Peter Thiel, who started out by giving young people $100,000 to skip college and work on their ideas, has established Breakout Labs to fund early-stage companies with radical ideas. The National Institutes of Health is getting into the action with its "skip the post-doc" Early Independence Awards to help free exceptional young minds from the academic treadmill. Jimmy Lin's Rare Genomics Institute is crowdfunding genomic sequencing for patients with rare diseases -- and there's much discussion about crowdfunding's utility in life sciences. Crowdsourcing is gaining traction in life sciences, from FoldIt's online protein folding games to Transparency Life Sciences' crowdsourced clinical study design. Who will be redefining "the box" in 2013? You tell us -- send us your ideas at [email protected]

16 ноября 2012, 14:41

Великобритания/США: компания Reckitt Benckiser сделала предложение по покупке Schiff за $1,4 млрд

Британский производитель бытовых чистящих средств Reckitt Benckiser Group сделал предложение по приобретению американского производителя пищевых добавок и витаминов Schiff Nutrition International за $1,4 млрд, что превзошло предложение, озвученное крупнейшим в Германии фармацевтом Bayer. Следует отметить, что заявленная сумма на 24% превышает последнюю цену закрытия акций Schiff Nutrition.

Выбор редакции
30 октября 2012, 13:51

Bayer diversifies with $1.2bn Schiff deal

German group bets on ‘nutraceuticals’ with acquisition of US company, the latest in a growing shift beyond doctor-prescribed medicines

Выбор редакции
29 октября 2012, 15:06

Overnight Sentiment: Cloudy, If Not Quite Frankenstormy

It is cloudy out there as Sandy enters the mid-Atlantic region, although for all the pre-apocalypse preparations in New York, the Frankenstorm may just be yet another dud now that its landfall is expected to come sufficiently south of NYC to make the latest round of Zone 1 evacuations about overblown as last year's Irene hysteria (of course it will be a gift from god for each and every S&P company as it will provide a perfect excuse for everyone to miss revenues and earnings in Q4). That said, Wall Street is effectively closed today for carbon-based lifeforms if not for electron ones, and a quick look at the futures bottom line, which will be open until 9:15 am Eastern, shows a lot of red, with ES down nearly 10 ticks (Shanghai down again as the same old realization seeps day after day - no major easing from the PBOC means Bernanke and company is on their own) as the Friday overnight summary is back on again: Johnny 5 must defend 1400 in ES and 1.2900 in EURUSD at all costs for just two more hours. What has happened so far for those who aren't happily in bed expecting all hell to break loose. In a nutshell: Spanish retail sales implode -12.6% from -2.0% last as VAT hike kicks in (it's all Jorge Bush' fault) German government spokesman says not sure when Troika report on Greece will be complete and that no Greek OSI is coming - so no distressed exchange, and no OSI... suddenly that long GGB2 "slam-dunk" rerun not looking too hot. Japan FinMin Jojima calls on BoJ to take bold policy steps to help beat deflation BoE Chief Econ Dale growth to falter after Olympic boost. BoE MPC Bean Q4 may be weak, economy bumping along bottom despite Q3 data, some headwinds abating however. Greek FinMin Strounaras EU/IMF lenders refuse to concede on reforms. Greek FinMin to show reforms progress at Wednesday EuroGroup meeting. Troika seeks 150 new Greek reforms - Der Spiegel. ECB's Draghi Talks Down Inflation Risks, Urges Pooling of Sovereignty Spain to announce bad bank details at 5pm Madrid time And while everything may be closed, events will still happen. Here is what is on the docket for today and the rest of the week via Goldman Sachs: One of the key focus points for FX markets next week will be Japan. Given that we continue to expect worse trade numbers out of Japan for October and coupled with the sluggish consumption stemming from the termination of the eco-car subsidies, we expect the BOJ to lower its inflation and growth outlook and announce additional easing at the upcoming meeting. We think that a JPY10tn increase in the Asset Purchase Program is the most probable. The BOJ could also commit to continuing its Asset Purchase Program until core inflation reaches 1% though this is less likely. There are a slew of other Central bank meetings this week. We expect the central banks of Norway, Russia and the Czech MPC to stay on hold and we continue to forecast a 25bp cut for Hungary and Israel by the end of this year. The RBI is expected to cut the cash reserve ratio by 25bp while leaving the repo rate unchanged at 8.00% given the weak inflation print for September. On the data front, the next week should give us more clarity on the outlook for US growth, as we get the US Manufacturing ISM and US labor market data, including ADP Employment and Non-Farm Payrolls numbers for October. We continue to look for signs of a sustained recovery in Chinese domestic activity. We get the official China PMI and the final HSBC PMI early on Thursday morning which could be expected to pick up modestly given the strong Flash print. In October, our Advanced GLI momentum improved to 0.9%mom from September’s reading of -0.01%mom, making this the first time momentum has been positive and increasing since December 2011, a strong signal for improvement in the global cycle. Given that the Korean exports print out on Wednesday is expected to increase sharply over October, as revealed by the 20-day exports number, we will look at the Global PMI releases on Thursday to see whether GLI Momentum will remain in the ‘Expansion phase’ for our October Final GLI print with its broader set of components. The Week Ahead Monday October 29 Israel MPC: Consensus expects no change to the overnight rate at 2.25% German CPI (October): With the growing tension between the Bundesbank and the ECB and given the strict ECB inflation mandate it is important to look for signs of inflation in Germany as this might reduce the scope for additional policy easing. That said, consensus expects 1.9%yoy down from 2.0%yoy from September. Japan IP (September): Consensus expects -3.1%mom down from -1.6%mom in August. ECB Weidmann Speech Also Interesting: US Personal Income, US Personal Spending Tuesday October 30 Japan Monetary Policy Meeting: The BOJ will release its biannual Outlook Report at this meeting. We expect the BOJ to lower the inflation and growth outlook and announce additional easing with the highest probability assigned to an extension of the Asset Purchase Program budget by JPY10 tn. While less likely we also think that the BOJ might commit to continuing its Asset Purchase Program until core inflation reaches 1% India RBI Meeting: We and consensus expect the RBI to leave the repo rate unchanged at 8.00% given the weak inflation print in September. Consensus also expects a cut to the cash reserve ratio from 4.50% to 4.25%. Spain GDP (2012-Q3): We and consensus expect the Spanish economy to contract by 0.4%qoq unchanged from 2012 Q2. Hungary MPC: Consensus expects a 25bps cut to the base rate currently at 6.50%. Brazil IGP Inflation (October): We expect 7.62%yoy; consensus expects 7.64%yoy down from 8.07%yoy in September. US Consumer Confidence (October): We expect 74.0 and consensus expects 72.5 up from 70.3 in September Fed Dudley Speech ECB Draghi Speech Also Interesting: Euro area Consumer Confidence, Germany Unemployment, South Korea IP Wednesday October 31 Norway Monetary Policy Meeting: We and consensus expect no change deposit rates at 1.50%. South Korea Exports (October): Korean 20-day exports rose sharply in October by the most in 10 months, most likely boosted by recovering China domestic activity and better US data. Consensus expects -0.5%yoy up from -2.0%yoy in September. US Chicago PMI (October): We expect 51.0, consensus expects 51.4 up from 49.7 in September. Also Interesting: UK Consumer Confidence, Euro Area CPI, Canada GDP, South Korea CPI Thursday November 1 Global PMI’s (October) Russia MPC: Consensus expects no change to the overnight auction-based repo-rate at 5.5% United States ADP Employment Change (October): Consensus expects 137.5K down from 162.0K in September US ISM (October): We expect the October ISM number to print lower at 50.5. Consensus expects 51.1 down from 51.5 for September. Also Interesting: Czech MPC, Brazil IP, US Initial Jobless Claims, US Non-Farm Productivity Friday November 2 Euro-area Manufacturing PMI (October): We expect the Euro area final estimate to print at 45.3 in line with the flash PMI. This is consistent with -0.4%qoq GDP growth in the Euro area. Consensus expects 45.3 unchanged from 45.3 in September. US Non-Farm Payrolls (October): We expect the payrolls number from September to be 125K; consensus expects 124K up from 114K in August. US Unemployment Rate (October): We and consensus expect 7.9% up from 7.8% in September * * * And a comprehensive recap of recent events via Deutsche Bank: We don’t often begin the EMR with the weather but today’s headlines will likely be filled with updates on what could be the largest storm in history to hit the mainland of the United States. Hurricane Sandy is forecasted to make landfall late Monday night and is already causing disruptions to several modes of transportation along the eastern seaboard. New York City’s subway, bus and train services have been shut, 5,000 flights have been cancelled ahead and Amtrak services in the Northeast Corridor north of New York have been stopped ahead of the hurricane’s arrival. As for the market the NYSE will be fully closed today (and possibly tomorrow pending confirmation) after having earlier planned to only close its physical trading floor and allow electronic trading to continue. A rare occasion indeed as it would be the first weather-related closure of the stock exchange since Hurricane Gloria hit in 1985. In other markets, the CME announced that its floor trading on the NYMEX oil market will be suspended today but electronic trade at all of CME will open at their regularly scheduled time. The Securities Industry and Financial Markets Association (Sifma) has called for fixed income securities trading to end mid-day today. Hurricane Sandy aside we have an eventful week in the US with the final payrolls and unemployment report before next Tuesday’s election being the main data to watch. Personal Income/Spending today, Consumer Confidence tomorrow, Chicago PMI on Wednesday and the ISM on Thursday are also key releases this week. In terms of the earnings season, we have 114 of the S&P500 companies lined up this week with Ford, Pfizer (Tues), Visa, Mastercard (Wed) Exxon (Thurs) and Chevron (Fri) being the more notable firms to report. In Europe, Germany’s employment data and Eurozone confidence surveys are scheduled for Tuesday. This will be followed by Euro-wide CPI and unemployment data on Wednesday, together with the ECB’s latest bank lending survey on the same day. Spain is due to redeem EUR20.3bn of bonds in the first half of the week. Earnings season will also pick up pace in Europe this week as 66 Stoxx600 companies are expected to report. UBS, Bayer, BP, Barclays, BBVA, Royal Dutch Shell, and RBS to name a few are the key ones. Asian markets are trading mixed overnight, led by losses on the Shanghai Composite (-0.36%) and Hang Seng (-0.33%). The property-heavy Hang Seng index is underperforming following the Hong Kong Government’s announcement of a new 15% stamp duty for non-local buyers of real estate, in addition to new taxes on homes resold within three years of purchase. In China, official industrial profits data for September were released on the weekend which showed the first monthly increase in profits in five months (+7.8%yoy), although year-to-date profits remain down 1.8%yoy, led by the poor performance of metal smelting firms (-68%yoy). The Nikkei is outperforming (+0.03%) despite weaker than expected retail trade numbers (-3.6% vs -1.5% expected), which is perhaps adding further weight to calls for the BoJ to expand asset purchases when it meets tomorrow. On that note, a Bloomberg survey indicated that all but one of 27 economists surveyed expect the BoJ to ease further at tomorrow’s meeting. Japanese retail sales and IP as well as Chinese PMIs are the key Asian data this week. Away from equities, credit markets are generally softer overnight with the Asian and Australian IG indices 4bp and 1bp wider, respectively. It was a relatively quiet weekend in terms of news with developments in Greece the main headlines of note. According to Der Spiegel, the troika are proposing a restructuring of Greek debt in addition to giving Greece two more years to reach fiscal targets. German FM Schauble said over the weekend that he is against further Greek debt haircuts but a Greek debt buyback is “something one could consider more seriously” (Ekathimerini). The same newspaper is reporting that the Greek government faced a Sunday deadline to reach full agreement on the EU13.5bn in austerity measures in order to get its next bailout tranche payment of EU31.5bn. The Euro Working Group (EWG) of eurozone finance ministry officials will convene again on Monday to discuss the conclusions Athens has come to, followed by a Wednesday video conference. Away from Greece, Italy’s former PM Berlusconi said that the People of Liberty party is considering withdrawing support for Monti’s government claiming that Monti’s policies are driving Italy into a deeper recession. Party officials were downplaying Berlusconi’s comments, adding that the former PM did not have the support of party members to bring the government down (FT). Finally, with just over a week before the US Presidential election, the latest Reuters/Ipsos poll showed Obama enjoying a small edge over Romney (49% vs 46%), although it appears increasingly likely the result will boil down to results in a handful of key swing states.

Выбор редакции
27 августа 2012, 19:45

Blood Thinner Cuts Repeat Heart Attack Risk In Trial

FRANKFURT, Aug 27 (Reuters) - Bayer said results from a late-stage clinical trial showed its anti-clotting pill Xarelto cut the risk of recurrence in patients who have suffered a severe heart attack, as it strives to secure U.S. approval for wider use of the drug. Results from the trial showed that adding Xarelto to standard therapy - typically aspirin and Sanofi's Plavix - significantly reduced cardiovascular death, heart attack or stroke compared with standard therapy alone. The results came from the analysis of a sub-group of patients in a wider drug trial that tested the blood clot preventer on patients with acute coronary syndrome (ACS). Based on the wider trial, U.S. regulators in June declined to extend the use of Xarelto to include ACS patients due to concerns over bleeding risks. Bayer and development partner Johnson & Johnson are currently trying to answer the FDA's questions to secure an approval. Patients with ACS have had heart attacks or chest pains that indicate the risk of a heart attack. About 30 percent of ACS patients have actually suffered a severe form of heart attack, so-called ST-segment elevation myocardial infarction (STEMI), Those were the subject of the study which was published on Monday. STEMI typically involves an obstructed coronary artery, leading to damage of the heart muscle tissue. In the narrower analysis with about 8,000 participants, patients on Xarelto incurred a higher risk of major bleeding - a typical concern linked to any anti-clotting treatment - than those on standard treatment alone. Xarelto, however, did not increase the rate of fatal bleeding, Bayer added. Bayer has submitted Xarelto for European approval for prevention of heart attacks in ACS patients and is expecting a decision by the end of this year.

15 сентября, 07:56

Monsanto в Европе и революция в России

Bayer наконец-то купил Monsanto! Казалось бы, в первую очередь это проблема для европейских фермеров. Чего волноваться нам? (14.09.2016)«Expert Online» Немецкий концерн Bayer объявил о заключении сделки с американским производителем генно-модифицированных семян и гербицидов Monsanto по цене $128 за акцию. Советы директоров обеих компаний единогласно одобрили слияние. ...Выручка объединенной структуры по итогам 2015 года могла бы достигнуть 23 млрд евро. После объединения компании будут совокупно контролировать около 30% мирового урожая. Акции Bayer на фоне информации о сделки прибыли 2,2%, Monsanto подорожали на 0,2%. (конец цитаты) Но с того дня, как 30% рынка сельхозпродукции окажутся под контролем двух фирм, в недалеком прошлом участвовавших в человеконенавистнических проектах: первая входила в концерн IG Farben (владел 42,5 % акций компании, которая производила Циклон Б), а вторая производила «Агента «оранж» для британской и американской армий, который распылялся с самолетов для уничтожения растительности на территории повстанцев. Неудивительно, что корпорации-носители такого прошлого теперь объединились в своей борьбе с населением планеты.